Eledon Free Cash Flow Yield vs Free Cash Flow Per Share Analysis
ELDN Stock | USD 4.50 0.03 0.67% |
Eledon Pharmaceuticals financial indicator trend analysis is much more than just examining Eledon Pharmaceuticals latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Eledon Pharmaceuticals is a good investment. Please check the relationship between Eledon Pharmaceuticals Free Cash Flow Yield and its Free Cash Flow Per Share accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.
Free Cash Flow Yield vs Free Cash Flow Per Share
Free Cash Flow Yield vs Free Cash Flow Per Share Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Eledon Pharmaceuticals Free Cash Flow Yield account and Free Cash Flow Per Share. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Eledon Pharmaceuticals' Free Cash Flow Yield and Free Cash Flow Per Share is 0.91. Overlapping area represents the amount of variation of Free Cash Flow Yield that can explain the historical movement of Free Cash Flow Per Share in the same time period over historical financial statements of Eledon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Eledon Pharmaceuticals' Free Cash Flow Yield and Free Cash Flow Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow Yield of Eledon Pharmaceuticals are associated (or correlated) with its Free Cash Flow Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Per Share has no effect on the direction of Free Cash Flow Yield i.e., Eledon Pharmaceuticals' Free Cash Flow Yield and Free Cash Flow Per Share go up and down completely randomly.
Correlation Coefficient | 0.91 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Free Cash Flow Yield
A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.Free Cash Flow Per Share
The amount of cash a company generates after accounting for capital expenditures, divided by the number of outstanding shares. It represents the cash available for dividends, share buybacks, or debt repayment per share.Most indicators from Eledon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Eledon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.Eledon Pharmaceuticals reported last year Tax Provision of (579,000). As of the 17th of December 2024, Enterprise Value Over EBITDA is likely to grow to 0.25, while Selling General Administrative is likely to drop about 10.4 M.
Eledon Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Eledon Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Eledon Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.9M | 197.2M | 170.5M | 92.8M | 125.9M | 81.1M | |
Other Current Liab | 813K | 829K | 1.9M | 3.5M | 2.5M | 2.1M | |
Total Current Liabilities | 1.3M | 2.5M | 4.4M | 6.5M | 3.9M | 3.7M | |
Total Stockholder Equity | 9.5M | 190.6M | 164.0M | 84.2M | 83.4M | 60.7M | |
Property Plant And Equipment Net | 321K | 138K | 768K | 739K | 365K | 278.2K | |
Net Debt | (8.5M) | (114.1M) | (84.1M) | (55.7M) | (4.2M) | (4.4M) | |
Retained Earnings | (57.6M) | (80.4M) | (114.9M) | (202.9M) | (243.2M) | (231.0M) | |
Accounts Payable | 329K | 1.4M | 1.8M | 2.2M | 967K | 1.0M | |
Cash | 8.8M | 114.2M | 84.8M | 56.4M | 4.6M | 4.4M | |
Non Current Assets Total | 960K | 81.6M | 82.2M | 33.3M | 69.8M | 73.3M | |
Non Currrent Assets Other | 639K | 383K | 400K | 150K | 186K | 309.2K | |
Cash And Short Term Investments | 8.8M | 114.2M | 84.8M | 56.4M | 51.1M | 53.7M | |
Common Stock Shares Outstanding | 655.5K | 1.5M | 14.8M | 14.3M | 24.6M | 25.9M | |
Liabilities And Stockholders Equity | 10.9M | 197.2M | 170.5M | 92.8M | 125.9M | 81.1M | |
Non Current Liabilities Total | 144K | 4.1M | 2.2M | 2.1M | 38.6M | 40.5M | |
Other Current Assets | 54K | 1.3M | 3.5M | 3.1M | 5.0M | 5.3M | |
Other Stockholder Equity | 67.0M | 271.0M | 278.9M | 287.0M | 326.6M | 166.9M | |
Total Liab | 1.5M | 6.6M | 6.6M | 8.6M | 42.5M | 44.6M | |
Property Plant And Equipment Gross | 321K | 138K | 768K | 739K | 365K | 278.2K | |
Total Current Assets | 10.0M | 115.6M | 88.3M | 59.5M | 56.1M | 56.0M | |
Common Stock Total Equity | 7K | 9K | 13K | 15K | 13.5K | 12.8K | |
Common Stock | 9K | 13K | 15K | 14K | 24K | 13.1K | |
Net Tangible Assets | 12.6M | 9.5M | 109.6M | 83.0M | 95.4M | 100.2M | |
Property Plant Equipment | 14K | 321K | 138K | 768K | 883.2K | 927.4K | |
Net Invested Capital | 9.5M | 190.6M | 164.0M | 84.2M | 83.4M | 88.9M | |
Net Working Capital | 8.6M | 113.1M | 83.9M | 53.0M | 52.2M | 53.5M |
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eledon Stock
0.67 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
Moving against Eledon Stock
0.84 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
0.78 | LLY | Eli Lilly Sell-off Trend | PairCorr |
0.76 | PFE | Pfizer Inc Aggressive Push | PairCorr |
0.73 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
0.65 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eledon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.73 | Return On Assets (0.33) | Return On Equity (0.25) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.